NRL Capital Asset Manager Profile - aVenture Research
NRL Capital, based in Beijing, is a prominent financial services firm and China's largest PSD fund. The company focuses on investments in the biotechnology and medical technology sectors, with a particular interest in early-stage and growth-stage companies. Their investment range spans from seed rounds to Series B funding.
Notable portfolio companies include Aureka Biotechnologies, which has raised $10 million, and Ronovo Surgical, with a total funding of $200 million. NRL Capital's investment strategy appears to target innovative companies in the healthcare sector, potentially offering valuable industry connections and expertise to support their portfolio companies' growth in the Chinese market.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.